# Rezolute Reports 13 of 16 Patients Achieved at Least 50% Glucose Infusion Rate Reduction

By John Kim

Canonical URL: https://www.tokenpost.com/news/business/56746
Published: 2026-11-13T14:10:47.000Z
Updated: 2026-11-13T14:10:47.000Z
Section: Business

> The Phase 3 upLIFT study is evaluating ersodetug for tumor hyperinsulinism.

Rezolute announced preliminary interim results from its Phase 3 upLIFT study of ersodetug for tumor hyperinsulinism; 13 of 16 patients achieved at least a 50% reduction in glucose infusion rate from baseline.